United Lab (03933) shares rose more than 3%, up 3.53% as of press time to HK$7.925, with turnover of HK$25.5406 million.

On the news front, United Lab recently announced that its wholly-owned subsidiary Zhuhai United Laboratories Biopharmaceutical Co., Ltd. has received acceptance from China's National Medical Products Administration for the marketing registration application of its independently developed Insulin Degludec and Liraglutide Injection (IDegLira). The company is the first in China to submit a marketing registration application for a biosimilar of Insulin Degludec and Liraglutide Injection.

According to the company, Insulin Degludec and Liraglutide Injection is a long-acting compound glucose-lowering formulation composed of basal insulin degludec (IDeg) and human glucagon-like peptide-1 (GLP-1) analogue liraglutide. The two components maintain their respective pharmacokinetic characteristics within the compound formulation, achieving complementary advantages and synergistic effects that break through the limitations of monotherapy, enabling all-day stable glucose control, significantly improving blood glucose attainment rates, and addressing weight management and hypoglycemia risk control, delivering multiple clinical values of "glucose reduction, glucose stabilization, and safe weight control."